RT Journal Article
SR Electronic
T1 Persistence of functional memory B cells recognizing SARS-CoV-2 variants despite loss of specific IgG
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.15.21257210
DO 10.1101/2021.05.15.21257210
A1 Winklmeier, Stephan
A1 Eisenhut, Katharina
A1 Taskin, Damla
A1 Rübsamen, Heike
A1 Schneider, Celine
A1 Eichhorn, Peter
A1 Keppler, Oliver T.
A1 Klein, Matthias
A1 Mader, Simone
A1 Kümpfel, Tania
A1 Meinl, Edgar
YR 2021
UL http://medrxiv.org/content/early/2021/05/18/2021.05.15.21257210.abstract
AB While some COVID-19 patients maintain SARS-CoV-2-specific serum IgGs for more than 6 months post-infection, others, especially mild cases, eventually lose IgG levels. We aimed to assess the persistence of SARS-CoV-2-specific B cells in patients who have lost specific IgGs and analyzed the reactivity of the immunoglobulins produced by these B cells. Circulating IgG memory B cells specific for SARS-CoV-2 were detected in all 16 patients 1–8 months post-infection, and 11 participants had specific IgA B cells. Four patients lost specific serum IgG after 5–8 months but had SARS-CoV-2-specific-B-cell levels comparable to those of seropositive donors. Immunoglobulins produced after in vitro differentiation blocked receptor-binding domain (RBD) binding to the cellular receptor ACE-2, indicating neutralizing activity. Memory-B-cell-derived IgGs recognized the RBD of B.1.1.7 similarly to the wild-type, while reactivity to B.1.351 and P.1. decreased by 30% and 50%, respectively. Memory-B-cell differentiation into antibody-producing cells is a more sensitive method for detecting previous infection than measuring serum antibodies. Circulating SARS-CoV-2 IgG memory B cells persist, even in the absence of specific serum IgG; produce neutralizing antibodies; and show differential cross-reactivity to emerging variants of concern. These features of SARS-CoV-2-specific memory B cells will help to understand and promote long-term protection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the DFG (SFB TR128) and the MOMENTE program LMU (to SM).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethical committee of the medical faculty of the LMU Munich.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon request.